ImmunoGen Inc (IMGN)

[skitahoe]

Xena,

I think you know that I do respect what those who do the technical charting have to say, but clearly I'm no expert at interpreting them, nor do I place that much reliance on them.

I'm of the belief that IMGN is moving primarily on the strength of the news on a few drugs, as well as the failure of SGEN's drug. I think the charts reflect strength because of the news. I.E. the news results in positive charts, not that the stock is up because the charts look strong.

I believe that the dramatic reduction of stock price in 2016 wasn't warranted by the news that IMGN853 would need to do a full Phase 3 Trial, rather than a registrational Phase 2, yet we were punished because of that news. Now we see the drug apparently headed toward approval, and with a much larger label than would have been the case with the Phase 2 Trial, as well as positive news on other products that are both wholly owned, as well as partnered products.

In short, I believe the Street is starting to wake up to the fact that IMGN Technologies may be superior to SGEN's in many, if not all applications. If I'm correct about this, it's only a matter of time until IMGN's market cap exceeds that of SGEN, and while SGEN is falling, I still believe that the market cap will remain several billions.

Gary